ReviewAnnals of transplantation2017
Eculizumab in Renal Transplantation: A 2017 Update.
Review in Annals of transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 22 citations in OpenAlex.
- Innate immune modulation in transplantation: mechanisms, challenges, and opportunities.Frontiers in transplantation · 2023Review
- Impact of suboptimal donor to suboptimal recipient kidney transplant on delayed graft function and outcome.Frontiers in transplantation · 2023Article
- Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech children.European journal of pediatrics · 2020Article
- Molecular Mechanisms of AKI in the Elderly: From Animal Models to Therapeutic Intervention.Journal of clinical medicine · 2020Review
- Inflammaging and Complement System: A Link Between Acute Kidney Injury and Chronic Graft Damage.Frontiers in immunology · 2020Review
- Perspectives on the Optimal Genetically Engineered Pig in 2018 for Initial Clinical Trials of Kidney or Heart Xenotransplantation.Transplantation · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite ongoing progress in renal transplantation, there are still emerging challenges in this field, including consequences of ischemia-reperfusion injury (IRI), pre-existing and produced de novo anti-HLA donor-specific antibodies (DSA), and acute/chronic humoral rejection (AMR), as well as the recurrence of atypical hemolytic-uremic syndrome (aHUS) in genetically predisposed patients. All these conditions are related to the prominent role of the complement system and are deleterious to the fate of the renal graft. Eculizumab, a humanized monoclonal antibody directed against the complement C5a component, is currently being used in renal transplantation and was evaluated in several clinical trials to minimize the consequences of IRI, prevent or treat relapsing or de novo aHUS, and to prevent and cure humoral rejection in patients at high immunological risk. There are remaining issues in terms of defining precise indications, dosing, monitoring, and optimal duration of the therapy with this drug; however, eculizumab is an emerging drug in renal transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.